Hogan Lovells Advises HAEMATO AG on Sale of HAEMATO Pharm GmbH to PHOENIX Group

"Hogan Lovells has advised HAEMATO AG on the sale of its subsidiary HAEMATO Pharm GmbH to the PHOENIX group, a leading European healthcare provider. The transaction, which requires antitrust approvals, involves HAEMATO Pharm, a parallel importer focused on therapies for various medical conditions. This sale aligns with M1 Kliniken AG's strategy to enhance its position in the medical aesthetics sector. Financial details of the deal have not been disclosed."

Hogan Lovells advised HAEMATO AG on the sale of HAEMATO Pharm GmbH to the PHOENIX group. The transaction involved HAEMATO AG, a majority-owned subsidiary of M1 Kliniken AG, selling all shares in its subsidiary HAEMATO Pharm GmbH, a parallel importer specializing in therapies for HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology, to the PHOENIX group, a leading healthcare provider in Europe. The completion of the transaction is subject to customary antitrust approvals, and the financial terms have not been disclosed. The Hogan Lovells team for HAEMATO AG included: - Dr. Jan Philipp Feigen (Partner, Private Equity, Hamburg) - Dr. Malte Ingwersen (Counsel, Private Equity, Hamburg) - Dr. Sebastian Merkel (Associate, Private Equity, Hamburg) - Björn Thorben Stute (Projects Associate, Private Equity, Hamburg) - Christian Ritz (Partner, Antitrust, Munich) - Dr. Dennis Cukurov (Senior Associate, Antitrust, Munich) - Dr. Falk Loose (Counsel, Tax, Munich) - Peter Volkmann (Senior Associate, Tax, Munich)

Hogan Lovells Advises HAEMATO AG on Sale of HAEMATO Pharm GmbH to PHOENIX Group

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads